Safe if suggested It does not impact the ability to drive or operate machinery
New Delhi, April 1: Medications known as GLP-1 receptor agonists are rapidly gaining popularity in India for managing Type 2 Diabetes and obesity, prompting authorities to tighten oversight amid rising concerns over misuse and potential health risks
What is surprising is the reduction in the risk of heart attacks
Kavanagh DH, Tansey KE, O'Donovan MC, Owen MJ
Generic alternatives typically become available only after patent expiration and FDA approval of abbreviated new drug applications (ANDAs), a process that may take several years from the original approval date
Ozempic Effects on the Body: How Semaglutide Works Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for treating type 2 diabetes mellitus in adults